Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Chieti – page 4

116 clinical trials in Chieti, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Chieti at a glance
116
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

116 trials in Chieti

Open in trial search

Myocarditis

Recruiting

Study on the Safety and Effectiveness of Methylprednisolone Sodium Succinate and Sodium Chloride for Patients with Severe Cardiac Inflammation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:ASST Grande Ospedale Metropolitano Niguarda

Behcet's syndrome

Recruiting

Study on Apremilast for Treating Oral Ulcers in Children with Behçet's Disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Generalised tonic-clonic seizure+1

Recruiting

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Generalised tonic-clonic seizure

Recruiting

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Juvenile idiopathic arthritis

Recruiting

Study on Early Drug Withdrawal in Children with Juvenile Idiopathic Arthritis Using Secukinumab and Drug Combination for Those in Clinical Remission

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Abatacept
  • Sponsor:IRCCS Istituto Giannina Gaslini

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Obesity+1

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Deep vein thrombosis+1

Not yet recruiting

A study to evaluate the use of colchicine to reduce inflammation in patients with deep vein thrombosis.

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Universita' Degli Studi G. D'Annunzio Di Chieti

Partial seizures

Not yet recruiting

A study to evaluate the effectiveness and safety of vormatrigine in adults with focal epilepsy who are taking one to three anti-seizure medications.

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Vormatrigine
  • Sponsor:Praxis Precision Medicines Inc.

Diabetes mellitus+2

Not yet recruiting

A Study of Semaglutide for Diabetic Patients with Heart Attack or Unstable Angina to Measure Changes in Coronary Artery Plaque Using Imaging

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Azienda Ospedaliero-Universitaria Maggiore Della Carita

Type 2 diabetes mellitus

Not yet recruiting

Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Insulin degludec
  • Sponsor:Novo Nordisk A/S

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Chieti

What the registry says about research in the country

01 Neurology Studies

Innovative research focusing on multiple sclerosis treatments and management of Parkinson's disease. Clinical trials are evaluating new therapeutic approaches including frexalimab for relapsing MS and novel subcutaneous infusion therapies for advanced Parkinson's.

  • Multiple Sclerosis Treatment Comparisons
  • Parkinson's Disease Management
  • Neurological Disease Progression
02 Cardiovascular and Metabolic Research

Comprehensive studies examining treatments for type 2 diabetes and cardiovascular conditions. Research includes evaluation of tirzepatide and innovative approaches for stroke prevention in patients with atrial fibrillation.

  • Diabetes Management
  • Cardiovascular Disease Prevention
  • Heart Failure Treatments
03 Nephrology and Renal Studies

Advanced research in chronic kidney disease and end-stage renal disease, investigating novel dialysis solutions and treatment combinations. Studies focus on improving outcomes for patients requiring peritoneal dialysis.

  • End-Stage Kidney Disease
  • Peritoneal Dialysis Innovations
  • Renal Function Management
04 Dermatology Research

Clinical investigations of treatments for atopic dermatitis and other skin conditions. Studies evaluate new biological therapies and targeted treatments for various dermatological conditions.

  • Atopic Dermatitis Management
  • Prurigo Nodularis Treatment
  • Skin Disease Therapeutics
Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.